AB Science today touted results from a study of masitinib in combination with docetaxel in treating prostate cancer.
Paris-based AB Science presented the data at the 2021 American Urological Association (AUA) annual meeting, according to a news release.
Masitinib in combination with docetaxel as a first-line treatment of metastatic castrate refractory prostate cancer (mCRPC) eligible to chemotherapy proved a potential first-line treatment option in the study, the company said.
The prospective, placebo-controlled, double-blind, randomized phase 3 trial evaluated the drug combination with a primary analysis performed on a pre-specified targeted subgroup, defined as patients with baseline alkaline phosphatase levels (ALP) ≤250 IU/ml, and on the overall population.
AB Science’s primary endpoint for the study was progression-free survival (PFS), with the study being determined successful if improvement in median PFS relative to control reached a …